Radiation, chemotherapy, and immunotherapy for advanced rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of radiation therapy, a chemotherapy drug called NALIRIFOX, and an immunotherapy drug called adebrelimab for rectal cancer that has grown into nearby tissue or lymph nodes. The goal is to see if this combination helps shrink the tumor before surgery and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Diagnosed with locally advanced rectal adenocarcinoma (cancer that has grown beyond the rectal wall or into lymph nodes, but not spread to distant organs)
- Good overall health and ability to handle treatment (ECOG score 0–1, meaning you can do light activities or are mostly bedridden only part of the day)
- Normal blood counts, liver function, and kidney function based on recent lab tests
- Expected to survive at least 2 years
- No prior radiation therapy to the pelvis or abdomen
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of brief radiation therapy, two chemotherapy drugs (nal-IRI and capecitabine), and an immunotherapy drug (camrelizumab) for locally advanced rectal cancer. The goal is to shrink the tumor and improve outcomes before surgery.
This trial tests whether combining radiation and chemotherapy with two immunotherapy drugs can better treat locally advanced rectal cancer (no spread to distant organs). It may shrink the tumor before surgery, and if you are enrolled, you will receive this combination as part of the study.
This trial tests whether combining chemotherapy, immunotherapy (PD-1 inhibitor), and a precise type of radiation can help shrink locally advanced rectal cancer before surgery. It aims to improve treatment success and reduce side effects.
This trial tests a combination of a PD-L1 inhibitor (adebrelimab), short-course radiation, and chemotherapy given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This study tests a combination of radiation therapy, chemotherapy drugs (capecitabine and oxaliplatin), and two types of immunotherapy (a PD-1 blocker and IL-2) for locally advanced rectal cancer. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
This trial tests a combination of short-course radiation therapy followed by two chemotherapy drugs (NALIRIFOX) plus an immunotherapy drug (pucotenlimab) given before surgery for locally advanced rectal cancer. The goal is to shrink the tumor and improve outcomes for patients whose tumors have specific genetic markers and high-risk features.
Hear when a new Rectal Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.